Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies,
Read more